How much funding has Ocudyne raised?

Ocudyne has disclosed $9.1M raised across 4 rounds.

Where is Ocudyne headquartered?

Ocudyne is headquartered in Brooklyn Park, US.

Ocudyne

Brooklyn Park, US · Founded 2013 · Delaware corporation

OcuDyne develops an investigational ophthalmic device called OPTiC that is currently undergoing clinical trials in the United States. The company operates in the medical device and healthcare sector, focused on eye care applications.

Biotech Digital Health Healthtech Medical Devices

Founders & leadership

Jeff FrancoCEO

Jim NessCFO

Mike CalhounVP Research and Development

Luana WilburVP Clinical & Regulatory Affairs

Board

Joseph SmithBoard director

Jonathan TalamoBoard director

Reported raises · per SEC filings

Form D private placements

$9.1M disclosed across 4 rounds · 2016–2025

▶$5.7MraisedMar 2025 · 8 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Joseph SmithDirector
Jeffrey FrancoExecutive Officer, Director
Jonathan TalamoDirector

Offering amount: $12.1M
Amount sold: $5.7M
First sale: Feb 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2MraisedFeb 2019 · 1 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Jeffrey FrancoExecutive Officer, Director
Robert AtkinsonExecutive Officer, Director
Joseph SmithDirector

Offering amount: $3.2M
Amount sold: $2M
First sale: Jan 2019
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$886.5KraisedAug 2017 · 6 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Joseph SmithDirector
Jeffrey FrancoExecutive Officer, Director

Offering amount: $1.5M
Amount sold: $886.5K
First sale: Aug 2017
Incorporated: Corporation, Delaware, 2013
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$463KraisedOct 2016 · 5 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Joseph M. SmithDirector
Jeffrey FrancoExecutive Officer, Director

Offering amount: $500K
Amount sold: $463K
First sale: Oct 2016
Incorporated: Corporation, Delaware, 2013
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Oculis3 shared keywordsOculis is a biopharmaceutical company developing pharmaceutical drug products, with a focus on ophthalmic and eye disease treatments. It conducts formulation, process, and analytical development to advance drug candidates from early research through later development stages.

Companies competing with Ocudyne for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Ocudyne do?: OcuDyne develops an investigational ophthalmic device called OPTiC that is currently undergoing clinical trials in the United States. The company operates in the medical device and healthcare sector, focused on eye care applications.
How much funding has Ocudyne raised?: Ocudyne has disclosed $9.1M raised across 4 rounds.
Where is Ocudyne headquartered?: Ocudyne is headquartered in Brooklyn Park, US.